After dumping its sole remaining gene therapy asset last year, Pfizer has decided to exercise its option for global rights to Beam Therapeutics’ liver-targeted gene editing candidate.

Welcome back! The U.S. Supreme Court has struck down President Donald Trump’s emergency tariffs. Does this mean the global trade war is over? Let us know what you think. If this newsletter was ...

There are also plans to install solar-powered charging stations to provide more reliable sources of power, a key challenge ...

The FDA’s reversal of its earlier refusal to review mRNA-1010, the seasonal flu vaccine being developed by Moderna, accelerated a revival of Moderna shares that has been in progress over recent months ...

Pfizer Inc. remains a Strong Buy, offering compelling value with a 6.32% dividend yield and a P/E Non-GAAP of 8.43. Learn more about PFE stock here.

The company is turning its attention to long-term growth opportunities, including its $10 billion acquisition of obesity biotech Metsera, as per a report. Pfizer showcased the potential of that ...

Pfizer reported fourth-quarter revenue and earnings that topped estimates even amid dwindling demand for its Covid products. The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled ...

Full Year Revenue: $62.6 billion, a 2% operational decline from the previous year. Operational Revenue Growth (Excluding COVID-19 Products): 6% for the full year 2025. Adjusted Gross Margin: Expanded ...

Pfizer (PFE) came out with quarterly earnings of $0.66 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.63 per share a year ago. These figures are ...

Financials, information technology, and industrials are set to lead this week’s earnings calendar, with 359 companies scheduled to report. Four of the Magnificent Seven have already released results, ...